Member Info for Mozax

UT = 12.20p on 1300 shares.

This could move up significantly on a whisker.

341K & 250K printed red are buys, Shake o’clock.

Yes, I saw those too at the time.

With the quantity & quality of institutional investors here I anticipate some ‘smoke & mirrors’ whilst they position themselves, MIRI has multibag potential & after todays RNS ….. “which is a game changer for the industry & Mirriads Revenues”, there is going to be considerable institutional interest.

MCap is still only £10M.

With annual revenues capable of multiple millions in short order with programmatic how long can it stay this low?

Now up 27%.

1 MM on 3p

This RNS is so massive & the market has barely noticed, give it a bit of time though.

No wonder Rathbones have hoovered up nearly 20% on the quiet.

Moved

It’s about to pop, 2m iced to 2.5p, 3 want them at 2.

Up 14.29% already……

Absolutely massive RNS.

And remember, this presentation is from late last year, we’re 4 months on now.

There’s plenty of newsflow ahead…..

You can find it easily on YouTube.

You won’t be selling any once you’ve listened to it, the new CEO is excellent.

Just listen to the presentation if you haven’t already.

Revenues….

Great Traction….

FDA registration….

Great partners….

Help get the product into the US……

NICE recommendation ties down TRUSTS to use the test

Further designs for future tests……

Proper commercial traction…..

Pushing to sell products around the Globe…..

First to Market!!!

Got it, “Magic Moments” - one of his greats!

Perry Como?

Need to watch the presentation.

Cost of ADR’s ( Adverse Drug Reactions) to the NHS is approximately £2.2Bn.

GDR can affect circa 30% total market impact to NHS of around £660M.

Hold tight.

This was over 200p in 2020, and as I mentioned yesterday, when I started researching the Company, the assent to 200p was almost vertical from a base of 10p.

It can move extraordinarily quickly.

Indeed, Momentum is building here again……

Interesting Company, just reading up & researching.

Strategy for FDA approval- tick.

I note a Share Price of over 200p in 2020, from an almost vertical climb from 10p.

Mm’s seem to have sorted out liquidity and buying now available at 2.49p.

Current cash of over £8 Million & MCap £4M.

Interesting to see CEO & CFO share options granted at 14p, these were RNS’s recently on March 5th so there’s plenty of confidence for a good uplift.

Should have read:

“It would be good to see recent big buys as Director Buys”

Apologies, My previous post suggested they were, which was misleading.